A Global Powerhouse in Generic Pharmaceuticals
As the world’s leading provider of generic pharmaceuticals, Teva’s medicines help patients and consumers in a way that few other companies can.
Teva produces 73 billion tablets a year in 75 pharmaceutical and API facilities around the world. Some 2.7 million prescriptions are filled daily with Teva’s products in the EU, and an additional 1.5 million in the U.S. The scale and breadth of our generics portfolio has an unprecedented impact on global healthcare.
Teva’s exceptional integration of generics and specialty R&D enables us to generate a robust pipeline of high-value medicines, with an emphasis on complex and branded generics. Our R&D capabilities have expanded beyond tablets, capsules, liquids, ointments and creams to a broad range of effective dosage forms and delivery systems. In 2012 we launched 450 generic products.
Teva has a unique understanding of - and footprint in - world markets, where our generic medicines are tailored to the needs of local patients, physicians and consumers. We also have an unparalleled ability to partner in commercializing generic products, particularly in emerging economies.
Building on a remarkable track record of achievement, Teva continues to pursue a rich future in generics as we focus on patient needs, improving compliance, convenience, efficacy and safety, and providing affordable generic products to patients and society worldwide.
Teva has an important and growing global OTC business, primarily through a joint venture with The Procter & Gamble Company (P&G), which combines Teva’s production capabilities and market reach with P&G’s marketing expertise and expansive global platform. Teva intends to increase the presence of our joint venture with P&G in emerging markets, and to expand existing local brands into new geographies.